Svb Leerink reaffirmed their outperform rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report report published on Monday, Zacks.com reports. Svb Leerink also issued estimates for Fulcrum Therapeutics’ Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.26) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($3.24) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at ($1.15) EPS.
Several other analysts have also recently commented on the stock. Morgan Stanley initiated coverage on shares of Fulcrum Therapeutics in a research note on Monday. They issued an overweight rating and a $29.00 target price for the company. Bank of America initiated coverage on shares of Fulcrum Therapeutics in a research note on Monday. They issued a buy rating and a $19.00 target price for the company.
FULC stock traded up $0.05 during midday trading on Monday, hitting $10.20. The stock had a trading volume of 495 shares, compared to its average volume of 83,772. Fulcrum Therapeutics has a 12-month low of $10.08 and a 12-month high of $15.94.
In related news, Director Mark J. Levin acquired 81,250 shares of the stock in a transaction dated Monday, July 22nd. The stock was bought at an average cost of $16.00 per share, with a total value of $1,300,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder 6 Dimensions Capital, L.P. acquired 118,750 shares of the stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $16.00 per share, with a total value of $1,900,000.00. The disclosure for this purchase can be found here.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.